Table 2.
Median maternal angiogenic biomarker levels for the Nicotine exposure study group (n = 2278)
| Characteristics | N | % | sFlt-1, pg/mL | PlGF, pg/mL | sFlt-1/PlGF ratio | |||
|---|---|---|---|---|---|---|---|---|
| Median | IQR | Median | IQR | Median | IQR | |||
| Total biomarker study group | 2603 | 1258.0 | 938.0–1754.0 | 192.0 | 142.0–260.0 | 6.8 | 4.5–9.7 | |
| Nicotine exposure study group | 2278 | 1257.0 | 937.8–1753.0 | 193.0 | 143.0–261.0 | 6.7 | 4.4–9.7 | |
| Snus | 2278 | |||||||
| Never | 1762 | 77.3 | 1245.0 | 935.0–1729.3 | 195.0 | 144.0–263.0 | 6.6 | 4.4–9.6 |
| Stopped before pregnancy | 343 | 15.1 | 1334.0 | 971.0–1905.0 | 189.0 | 141.0–253.0 | 7.1 | 4.8–10.7 |
| Stopped when recognizing pregnancy | 160 | 7.0 | 1252.5 | 903.0–1752.8 | 183.5 | 143.3–265.0 | 7.1 | 4.6–9.4 |
| Current | 13 | 0.6 | 996.0 | 729.5–1392.5 | 166.0 | 93.5–204.5 | 6.6 | 5.2–8.9 |
| Smoking | 2217* | |||||||
| Never | 1762 | 79.4 | 1264.5 | 946.8–1754.3 | 192.0 | 143.0–261.3 | 6.8 | 4.5–9.8 |
| Stopped before pregnancy | 343 | 15.5 | 1238.5 | 915.3–1761.8 | 194.0 | 142.0–261.0 | 6.7 | 4.5–9.3 |
| Stopped when recognizing pregnancy | 97 | 4.4 | 1216.0 | 869.0–1687.0 | 189.0 | 142.0–247.5 | 6.7 | 4.6–9.9 |
| Current | 15 | 0.7 | 1146.0 | 820.0–1928.0 | 240.0 | 176.0–303.0 | 4.3 | 2.8–10.2 |
IQR, interquartile range; n, number; P, p-value; pg/mL, picograms per milliliter; PlGF, Placental Growth Factor; sFlt-1, Soluble Fms-like tyrosine kinase receptor 1; *, missing data